Wednesday, January 23, 2019

On the Record


"What we're left with is the health plans and the government agencies doing their best to keep up with these things as they come out and evaluating the evidence and making recommendations on them. That leads to some variation in opinions on whether tests should be paid for or not."
— Lon Castle, M.D., chief of molecular diagnostics and specialty drug management at eviCore healthcare, spoke with AIS's Health Plan Weekly about the variance in coverage of genetic testing across the spectrum of types of health insurance.

No comments:

Post a Comment